Healthcare Equipment and Supplies
Company Overview of EKOS Corporation
EKOS Corporation engages in the development and clinical application of ultrasound infusion technologies for the treatment of vascular thrombosis. The company develops EkoSonic and MicroSonic SV endovascular devices for the controlled and selective infusion of physician-specified fluids, including thrombolytics into the peripheral vasculature. Its products are used by interventional radiologists, cardiologists, and cardiothoracic and vascular surgeons at various institutions around the world. The company was founded in 1995 and is based in Bothell, Washington. As of July 5, 2013, EKOS Corporation operates as a subsidiary of BTG International Inc.
11911 North Creek Parkway South
Bothell, WA 98011
Founded in 1995
Key Executives for EKOS Corporation
Vice President and General Manager
Vice President of Regulatory & Clinical Affairs
Vice President of Systems Integration
Vice President of Operations
Compensation as of Fiscal Year 2015.
EKOS Corporation Key Developments
EKOS Corporation Announces the Publication of Results of the SEATTLE II Trial in the JACC: Cardiovascular Interventions
Aug 24 15
EKOS Corporation announced the publication of results of the SEATTLE II trial in the JACC: Cardiovascular Interventions. The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension in patients with intermediate to high risk PE. Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment. The SEATTLE II study was a prospective, single-arm, multi-center trial designed to evaluate the safety and effectiveness of ultrasound-facilitated catheter-directed low-dose thrombolysis, using the EKOS EkoSonic® Endovascular System. One-hundred fifty (150) patients diagnosed as acute massive (N=31) or submassive (N=119) PE were enrolled. Patients received low dose (24 mg) of tPA (thrombolytic) for 24 hours with a unilateral catheter or for 12 hours with bilateral catheters. The size of the right heart measured as RV/LV ratio significantly decreased from 1.55 to 1.13 (p<0.0001) by 48 hours after start of treatment. For patients with severe PE, the mortality rate is nearly one third1. In the SEATTLE II study 31 patients presented to the emergency room with massive PE, syncope and hypotension. All 31 survived the 30-day follow up period. Of 150 patients in the study, one death was directly attributed to PE. There were no intracranial hemorrhages and no fatal bleeding events. Major bleeds occurred in 15 patients and were comprised of one severe bleed and 16 moderate bleeds. Six of the major bleeds occurred in patients with co-morbidities known to be associated with an increased risk of bleeding during thrombolytic therapy.
EKOS Corporation Initiates a Pivotal New Study in Patients with Chronic Deep Vein Thrombosis and Post-Thrombotic Syndrome
Jun 11 14
EKOS Corporation announced the start of patient enrollment for the ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOS(R) System (ACCESS PTS) Study. The ACCESS PTS study is a prospective, single-arm, multi-center trial, designed to evaluate the safety and efficacy of ultrasound accelerated thrombolysis using the EkoSonic(R) Endovascular System with standard infusion of a thrombolytic drug for PTS and chronic venous occlusions. The study will enroll up to 200 subjects over a period of 12 months at approximately 30 study sites across the United States. Subjects will receive clinical follow-up for 12 months. Clinical effectiveness will be evaluated using the Villalta score (measurement of the severity of PTS) at baseline compared to 30 days post-EkoSonic(R) treatment. Success will be defined by 50% or more of the subjects achieving at least a 4 point reduction in the Villalta score, which represents a significant improvement in the symptoms of PTS. Potential study subjects will be between 18 and 75 years of age with lower extremity DVT who have: Been objectively diagnosed via imaging as having persistent DVT for at least 6 months. A Villalta score >=8. Failed 3 months of conservative treatment including compression stockings and anticoagulation drugs.
EkoSonic Endovascular System Receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA
May 23 14
EKOS Corporation announced that the U.S. Food and Drug Administration has cleared the EkoSonic Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism. The EKOS ultrasonic devices are designed to gently accelerate the penetration of thrombolytic agents into thrombus, providing high levels of lysis. EKOS is the only minimally invasive endovascular therapy on the market that has been FDA cleared for the treatment of PE.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|